Sanofi moves early on Beyfortus shipments to get ahead of demand

9 June 2025

French pharma major Sanofi (Euronext: SAN) has started early global shipments of its monoclonal antibody Beyfortus (nirsevimab), aiming to shore up supply ahead of the 2025–2026 respiratory syncytial virus (RSV) season.

Doses are being dispatched from early in the third quarter, giving healthcare providers more time to prepare for the season, which typically starts in November. Immunizations are expected to begin in the fall.

Beyfortus is the only preventative RSV medicine approved for all infants regardless of birth timing or medical condition. It has been co-developed with UK drugmaker AstraZeneca (LSE: AZN) and has seen rising demand since its launch in 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK